8-K: Picard Medical to Showcase Artificial Heart on FOX Business

Picard Medical, Inc. announced its SynCardia Total Artificial Heart and next-generation technology will be featured on BTV Business Television, airing on FOX Business News.

Summary

• Picard Medical, Inc. (PMI) will be featured on BTV Business Television.
• The segment is scheduled to air on FOX Business News on March 14, 2026, at 5:00 p.m. Eastern Time.
• The broadcast will highlight the SynCardia Total Artificial Heart (STAH) and the company's ongoing development of next-generation artificial heart technology.
• The STAH is the world's first total artificial heart approved by both the U.S. FDA and Health Canada.
• More than 2,100 STAH implants have been performed worldwide, making it the most widely used and extensively studied artificial heart technology globally.
• The STAH replaces both left and right ventricles and all four heart valves, restoring circulation in patients with severe biventricular heart failure awaiting transplantation.
• The company is developing a next-generation, fully implantable artificial heart platform designed to improve patient mobility and quality of life by eliminating external pneumatic drivers.
• CEO Patrick N.J. Schnegelsberg emphasized the growing importance of raising awareness for advanced heart failure therapies due to the increasing number of patients needing mechanical circulatory support.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for increasing brand visibility and investor awareness, particularly for a specialized medical device company, though it does not contain new financial or operational updates.

Positives

• Increased visibility and exposure for Picard Medical and its SynCardia Total Artificial Heart technology to retail and institutional investors via FOX Business News and BTV.
• Highlighting the SynCardia Total Artificial Heart's established track record with over 2,100 implants worldwide and its status as the most widely used and studied artificial heart globally.
• Showcasing the development of a next-generation, fully implantable artificial heart platform, which could significantly improve patient mobility and quality of life for patients.
• Raising awareness of advanced heart failure therapies, which is important given the growing number of patients needing mechanical circulatory support.

Negatives

• No immediate financial metrics or new product approvals were announced, as the filing is primarily a promotional announcement.
• The segment is scheduled for a Saturday at 5:00 p.m. EST, which might have lower viewership compared to prime weekday slots.

Risks

• Forward-looking statements involve risks and uncertainties that could cause actual results to differ from the forward-looking statements.
• The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements.
• Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed with the SEC.

Future Outlook

The company is advancing the next generation of artificial heart technology designed to further improve patient mobility and quality of life by eliminating external pneumatic drivers. Management believes raising awareness of advanced heart failure therapies is increasingly important as the number of patients in need of mechanical circulatory support continues to grow.

Management Comments

• "Raising awareness of advanced heart failure therapies is increasingly important as the number of patients in need of mechanical circulatory support continues to grow."
• "The SynCardia Total Artificial Heart has supported more than 2,100 patients worldwide by replacing the pumping function of a failing heart and providing critical time for patients awaiting transplantation."
• "We are also advancing the next generation of artificial heart technology designed to further improve patient mobility and quality of life."

Industry Context

StockSavvy.ai notes that increased media exposure on prominent financial networks like FOX Business News can significantly boost investor awareness for medical device companies, especially those in specialized, high-impact fields like artificial hearts. This aligns with a broader trend of companies leveraging media to highlight technological advancements and address growing patient populations in critical care areas.

Comparison to Industry Standards

• The SynCardia Total Artificial Heart (STAH) is highlighted as the most widely used and extensively studied artificial heart technology globally, with over 2,100 implants performed worldwide. This positions it as a leader in the total artificial heart segment, distinguishing it from other mechanical circulatory support devices like Left Ventricular Assist Devices (LVADs) which serve a different, though sometimes overlapping, patient population.
• The STAH is the only commercially available artificial heart approved by both the U.S. FDA and Health Canada, indicating a high regulatory bar met by the company.

Stakeholder Impact

• Shareholders: Potential for increased investor awareness and interest due to media exposure.
• Patients: Continued development of next-generation artificial heart technology aims to improve patient mobility and quality of life for those with severe heart failure.
• Medical Community: Increased awareness of advanced heart failure therapies and the SynCardia Total Artificial Heart's capabilities.

Next Steps

• The BTV Business Television segment featuring Picard Medical will air on FOX Business News on March 14, 2026, at 5:00 p.m. Eastern Time.
• The segment will also be available via replay through BTV's online distribution channels following the broadcast.
• Continued development of the next-generation, fully implantable artificial heart platform.

Key Dates

Recommendation

The filing primarily announces a media appearance, which is positive for increasing brand visibility and investor awareness. However, it does not contain new financial results, product approvals, or significant operational updates that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring for future substantive announcements.

Keywords

Picard Medical, SynCardia, Total Artificial Heart, TAH, Artificial Heart Technology, Heart Failure, Medical Devices, Biotechnology, FDA Approved, Health Canada Approved, BTV Business Television, FOX Business News